HRAS and keratoacanthoma: We identified oncogenic activating mutations in HRAS in three tumours (Fig. 3b and Supplementary Fig. 6), which have previously been identified in 3–20% of cSCC9,10 (Supplementary Data 13) and keratoacanthomas (reviewed in ref. 4).